Apple founder and CEO addresses health rumors as Macworld conference opens.
|
Japanese researchers find no ties to disease from cellphone radio waves.
|
Using mobile phones, drinking coffee, or having breast implants is unlikely to cause cancer, according to an Australian cancer specialist.
|
FDA mandates tough new warnings for anemia drugs Aranesp and Epogen.
|
U.S. Presidential candidate proposes legislation that would help bring generic versions of biotech drugs to market.
|
The maker of Cyberknife, a radiosurgery system that zaps tumors, joins its fiercest competition on the trading floor.
|
Neulasta and Neupogen may increase leukemia risk, but investors are doubtful.
|
Scientists look to find out why so many drugs fail in phase three.
|
U.S. Biopharma Cephalon named early inductee in “Global Growth” group.
|
Israel Roundup: Chip maker may sell flash division; $1.2 billion invested in venture-backed startups; Poalim and Plenus raise funds; Given Imaging leads cancer research consortium.
|
Privately-held Inologic grabs $1.07M U.S. government contract to boost surviving mass radioactive exposure.
|
For the second year in a row, deaths from dread disease drop—but new treatments are only part of the story.
|
Tanox shareholders approve the acquisition by Genentech.
|
European researchers genetically engineer chickens to lay eggs packed with cancer and MS drugs.
|
Drug developer scores deal worth $40M for work on cancer-fighting drugs.
|
Medical organization asks drug company to end case against government over patent.
|
Argos Therapeutics grabs U.S. government award to push novel HIV immunotherapy.
|
New price caps still leave cancer treatment beyond reach of most.
|
University researchers detect melanoma’s spread by listening for sound waves.
|
The diagnostic company gets ready to start trials to detect cancer early in women.
|
Page
1
of
6
|